Fibrovascular ingrowth in porous ocular implants: the effect of material composition, porosity, growth factors, and coatings.
OBJECTIVE
Fibrovascular ingrowth into various porous ocular implants as a function of implant material composition, porosity, growth factors, and coatings was investigated in a pilot study in an animal model.


METHODS
Eighty-one New Zealand white rabbits underwent unilateral enucleation and implantation with ocular implants composed of the following materials: coralline hydroxyapatite (HA) with 200-microm pores (HA200) or 500-microm pores (HA500), synthetic HA (synHA), and high-density porous polyethylene (PP). The HA200, HA500, and PP implants were implanted untreated or after treatment with recombinant human basic fibroblast growth factor (Rh-bFGF). Nine HA500 implants were implanted after coating with calcium sulfate (plaster of Paris) to provide a smooth outer surface. Implants were harvested at 1-, 2-, 4-, or 8-week intervals and were examined histologically.


RESULTS
A significant difference was found between untreated HA500 and PP, with PP showing better ingrowth. There was no significant difference between untreated HA and PP, nor between untreated HA500 and synHA. Significant increases in ingrowth were found in HA200 compared with HA500, and in Rh-bFGF-treated implants compared with untreated controls. The calcium sulfate-coated implants showed less vascularization compared with the uncoated implants, although the difference was not significant.


CONCLUSIONS
Fibrovascular ingrowth occurred earlier in HA200 implants than in HA500 implants, and was enhanced when implants were treated with Rh-bFGF.
Bigham
W J
WJ
Department of Ophthalmology, United States Navy Medical Corps, Naval Medical Center San Diego, CA 92134-5000, USA.
Stanley
P
P
Cahill
J M
JM
Curran
R W
RW
Perry
A C
AC
D000818:Animals; D002133:Calcium Sulfate; D002455:Cell Division; D002516:Ceramics; D020099:Coated Materials, Biocompatible; D017886:Durapatite; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology*; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects; D006882:Hydroxyapatites; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D020273:Orbital Implants; D020959:Polyethylene; D016062:Porosity; D019919:Prosthesis Implantation; D011817:Rabbits; D011994:Recombinant Proteins
D020099:Coated Materials, Biocompatible; D006882:Hydroxyapatites; D011994:Recombinant Proteins; C119955:coralline hydroxyapatite; D016222:Fibroblast Growth Factor 2; D020959:Polyethylene; D017886:Durapatite; D002133:Calcium Sulfate